MetaVia (MTVA) to Release Quarterly Earnings on Thursday

MetaVia (NASDAQ:MTVA) is expected to issue its Q4 2025 results before the market opens on Thursday, March 19th. Analysts expect the company to announce earnings of ($2.06) per share for the quarter. Parties may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Thursday, March 26, 2026 at 12:30 PM ET.

MetaVia Stock Performance

MetaVia stock opened at $1.63 on Thursday. The company has a market cap of $3.59 million, a P/E ratio of -0.19 and a beta of 0.33. MetaVia has a one year low of $1.34 and a one year high of $23.10. The business has a fifty day moving average of $3.22 and a two-hundred day moving average of $7.28.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in MetaVia stock. Virtu Financial LLC bought a new stake in shares of MetaVia Inc. (NASDAQ:MTVA) in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund bought 32,755 shares of the company’s stock, valued at approximately $31,000. Virtu Financial LLC owned about 0.14% of MetaVia at the end of the most recent reporting period. Institutional investors and hedge funds own 1.37% of the company’s stock.

Analyst Upgrades and Downgrades

MTVA has been the subject of several analyst reports. HC Wainwright boosted their price target on MetaVia from $12.00 to $40.00 and gave the company a “buy” rating in a report on Tuesday, January 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of MetaVia in a research report on Monday, December 22nd. Finally, Wall Street Zen lowered MetaVia from a “hold” rating to a “sell” rating in a research note on Saturday, January 31st. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $36.50.

MetaVia Company Profile

MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.